The prognostic value of sarcopenia in patients with prostate cancer: a systematic review

• Published in: Current opinion in urology Vol. 31; no. 4; pp. 315 - 323
• Main Authors: Jahrreiss, Victoria, Laukhtina, Ekaterina, D’Andrea, David, Shariat, Shahrokh F.
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-07-2021
• ISSN: 0963-0643; 1473-6586
• DOI: 10.1097/MOU.0000000000000885

Sarcopenia is known to affect perioperative and oncologic outcomes in patients with different urological malignancies. Nevertheless, the use of pretreatment sarcopenia as a predictor of clinical outcomes in patients with prostate cancer is still poorly studied. Therefore, we aimed to conduct a systematic review summarizing the available evidence and identifying the prognostic value of sarcopenia in prostate cancer patients.
Sarcopenia was not predictive of biochemical recurrence in patients treated with radical prostatectomy. However, it was associated with worse long-term survival outcomes as well as the likelihood of developing postoperative complications after radical prostatectomy. In the context of radiotherapy, sarcopenia was a predictive factor for overall survival. In patients with hormone-sensitive prostate cancer treated with androgen deprivation, sarcopenia was associated with overall and cancer-specific survival. In patients with castration-resistant prostate cancer, sarcopenia was associated with poorer tolerance to docetaxel-based chemotherapy.
Most studies found sarcopenia to be a predictor for worse perioperative and oncologic outcomes in patients treated with radical surgery, radiotherapy, or systemic therapy for prostate cancer. However, there is significant heterogeneity across the studies in terms of sarcopenia definition. For a better understanding of the prognostic value of sarcopenia in patients with prostate cancer, large-scale prospective studies are needed.